Drug Profile
Epicardial angiogenesis patch - Theregen Corporation
Alternative Names: AngineraLatest Information Update: 08 Apr 2016
Price :
$50
*
At a glance
- Originator Theregen
- Class Fibroblast cell therapies
- Mechanism of Action Angiogenesis inducing agents; Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Heart failure; Ischaemic heart disorders
Most Recent Events
- 07 Dec 2007 Theregen completes enrolment in its phase I trial for Ischaemic heart disorders in USA
- 25 Jul 2007 Phase-I clinical trials in Heart failure in USA (Perilesional)
- 10 May 2006 Phase-I clinical trials in Ischaemic heart disorders in USA (Perilesional)